Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL4622706

CCCC[N+](CCCC)(CCCC)CCCC.CCOP(=O)([O-])OCC

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
AKT1 P31749 2/20 0.53
ESR1 P03372 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CDC25A P30304 1/20 0.53
AGTR1 P30556 1/20 0.53
ADRA1A P35348 1/20 0.53
KCNH2 Q12809 1/20 0.53
SLC22A1 O15245 3/20 0.50
SLC22A2 O15244 1/20 0.44
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diethyl Hydrogen Phosphate SCHEMBL625867 0.92 LMNA (0.46) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19821338 0.90 LMNA (0.45) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL26929180 0.88 SLC22A1 (0.50) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL29773383 0.86 SLC22A1 (0.48) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL29773382 0.86 SLC22A1 (0.48) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL5144551 0.86 SLC22A1 (0.48) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL6382222 0.86 AKT1 (0.66) LMNAAKT1ESR1ADORA3CDC25A
Tributylmethylammonium SCHEMBL3267256 0.86 LMNA (0.51) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL19834900 0.84 SLC22A1 (0.71) LMNAAKT1ESR1ADORA3CDC25A
Tetrabuthylammonium SCHEMBL49814 0.84 SLC22A1 (0.71) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 US disclosed
WO-2023238500-A1 TREATMENT AGENT FOR CARBON FIBER PRECURSOR, AND CARBON FIBER PRECURSOR 竹本油脂株式会社 2023-12-14 WO disclosed
CN-117157295-A Indoline-containing spiro derivative, preparation method and medical application thereof 长春金赛药业有限责任公司 2023-12-01 CN disclosed
EP-4282867-A1 INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2023-11-29 EP disclosed
WO-2022228318-A1 INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE 长春金赛药业有限责任公司 2022-11-03 WO disclosed
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-07-11 US disclosed
EP-1554327-B1 CELLULAR POLYURETHANE ELASTOMERS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF BAYER MATERIALSCIENCE AG (DE) 2008-03-26 EP disclosed
EP-1554327-A1 CELLULAR POLYURETHANE ELASTOMERS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF Bayer MaterialScience AG (DE) 2005-07-20 EP disclosed
WO-2004035648-A1 CELLULAR POLYURETHANE ELASTOMERS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF BAYER MATERIALSCIENCE AG (DE) 2004-04-29 WO disclosed
US-20040077740-A1 Cellular polyurethane elastomers, a process for preparing these and their use BAYER AKTIENGESELLSCHAFT (DE) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF GHSR, GHRHR, NR3C2 LMNA 1688/4885AKT1 645/4885ESR1 891/4885
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES HSP90B1, HSP90AB1, HSP90AA1 LMNA 2423/4885AKT1 2286/4885ESR1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.